Neuroendocrine tumors: aspects of diagnosis (literature review)


  • A.M. Kvachenyuk State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
  • D.A. Kvachenyuk State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine



neuroendocrine tumor, carcinoid, APUD-system, chromogranin А, carcinoid syndrome, review


The paper analyzes the literature on the problem of the management of patients with neuroendocrine tumors both from a historical perspective and from a modern aspect. Particular attention is paid to classifications, clinical diagnostic and laboratory diagnostic stages of the management of a patient with neuroendocrine tumors, especially the study of biological markers.


Download data is not yet available.


Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol: 1907. 425–429р.

Padberg B, Schröder S, Capella C, Frilling A, Klöppel G, Heitz PU. Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch. 1995;426(6):541–548. doi:10.1007/bf00192107.

Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–597. doi:10.1002/cncr.29099.

Singh S, Granberg D, Wolin E, et al. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol. 2016;3(1):43–53. doi:10.1200/JGO.2015.002980. 

Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. doi:10.1200/JCO.2007.15.4377.

Stridsberg M, Oberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144(1):49–59. doi:10.1677/joe.0.1440049.

Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20(2):187–196. doi:10.1530/ERC-12-0340.

Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11(1):1–18. doi:10.1677/erc.0.0110001.

Kulke MH. Neuroendocrine tumours: clinical presentation and management of localized disease. Cancer Treat Rev. 2003;29(5):363–370. doi:10.1016/s0305-7372(03)00072-0.

Rindi G, Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer. 2003;10(4):427–436. doi:10.1677/erc.0.0100427.

Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0124884. doi:10.1371/journal.pone.0124884. 

Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30(3):417–422. doi:10.1007/s00259-002-1050-8.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62S–6S.

Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–e446. doi:10.1016/S1470-2045(15)00186-2.

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–712. doi:10.1097/MPA.0b013e3181ec124e.

O'Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90(2):194–202. doi:10.1159/000225948.

Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33(16):1855–1863. doi:10.1200/JCO.2014.60.2532.

McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23nd ed. Louis, Missouri: Elsevier; 2016. 1584p.

Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol. 2004;39(10):969–973. doi:10.1080/00365520410003362.

Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17(9):2427–2443. doi:10.1245/s10434-010-1006-3.



How to Cite

Kvachenyuk, A., & Kvachenyuk, D. (2021). Neuroendocrine tumors: aspects of diagnosis (literature review). INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 16(1), 44–49.



Literature Review